The influence of gemcitabine on the CD4/CD8 ratio in patients with solid tumours

Oncology Reports

Volumn 4, Issue 3, 1997, Pages 561-564

  Daikeler, Thomas ^a   Maas, Kathrin ^a   Weiß, Burkhard ^a   Hartmann, Jörg Thomas ^a   Knobloch, Alois ^b   Arning, Michael ^c   Kanz, Lothar ^a   Bokemeyer, Carsten ^a,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF HOHENHEIM   (Germany)

^c LILLY DEUTSCHLAND GMBH   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

CD4 CD8 ratio; FACS; gemcitabine; infection; lymphocytes; solid tumours

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; GEMCITABINE;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE; THROMBOCYTOPENIA;

EID: 0031006384     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.3.561     Document Type: Article

References (16)

1. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J and Harris AL: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736, 1995.
2. Anderson H, Lund B and Bach F: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826, 1994.
3. Lund B, Hansen OP, Thcilade K, Hansen M and Ncijt JP: Phase II study of gemcitabine (2′2′difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533, 1994.
4. Carmichael J, Fink U, Russel RC, Spiltel MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic carcinoma. Br J Cancer 73: 101-105, 1996.
5. Huang P, Chubb S, Hertel LW, Grindey GB and Plunket W: Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
6. Tonato M: Gemcitabine safety overview: Gemcitabine, novel combination of efficacy and tolerability. Proc Eur Conf Clin Oncol 7, Satellite Symposium. Jerusalem, pp14-16, 1993.
7. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunket W, Frcireich EJ and McCredie KB: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74: 19-25, 1989.
8. Boldt DH, von Hoff DD, Kuhn J and Hersh M: Effects on human peripheral lymphocytes of in vivo administration of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purinc antimetabolite. Cancer Res 44: 4183-4186, 1984.
9. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F Jr, Rodriguez MA, Plunkett WK and Keating MJ: Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 10: 790-794, 1992.
10. FDA expands access to gemcitabine for pancreatic cancer. Am J Health Syst Pharm 52: 931, 1995.
11. Wijermans PW, Gerrits WBJ and Haak HL: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50: 292-296, 1993.
12. Carson DA, Kaye J and Wasson DB: Differences in deoxyadenosine metabolism in human and mouse lymphocytes. J Immunol 124: 8-12, 1980.
13. Cohen A, Hirschhorn R, Horowitz SD, Rubinstein A, Polmar SH, Hong R and Martin DW Jr : Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci USA 75: 472-476, 1978.
14. Montgomery JA: Studies on the biological activity of purine and pyrimidine analogues. Med Res Rev 2: 271-308, 1982.
15. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentation. Cancer Res 52: 4417-4422, 1992.
16. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P and Plunkett W: Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10: 406-413, 1992.